Recent improvements to enhance your investment research experience
360° View free for everyone
Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.
3 new subscription models
Plans for every investor - from stock ideas to in-depth analysis.
Similar Stocks
Four stock alternatives to the stock you're searching.
The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
| Metrics | Current | 2024 | 2023 | 2022 | 
|---|---|---|---|---|
| 
										
										Value
									 | 32 | 60 | 77 | 78 | 
| 
										
										Growth
									 | 15 | 40 | 31 | 15 | 
| 
										
										Safety
									 | 6 | 12 | 6 | 4 | 
| 
										
										Sentiment
									 | 82 | 37 | 36 | 6 | 
| 
										
										360° View
									 | 12 | 28 | 12 | 10 | 
| Metrics | Current | 2024 | 2023 | 2022 | 
|---|---|---|---|---|
| 
										Analyst Opinions
									 | 82 | 72 | 26 | 17 | 
| 
										Opinions Change
									 | 50 | 6 | 74 | 50 | 
| 
										Pro Holdings
									 | n/a | 23 | 37 | 46 | 
| 
										Market Pulse
									 | 85 | 67 | 49 | 17 | 
| 
										
										Sentiment
									 | 82 | 37 | 36 | 6 | 
| Metrics | Current | 2024 | 2023 | 2022 | 
|---|---|---|---|---|
| 
										
										Value
									 | 32 | 60 | 77 | 78 | 
| 
										
										Growth
									 | 15 | 40 | 31 | 15 | 
|  | 6 | 12 | 6 | 4 | 
| 
										
										Combined
									 | 1 | 17 | 16 | 12 | 
| Metrics | Current | 2024 | 2023 | 2022 | 
|---|---|---|---|---|
| 
										Price vs. Sales (P/S)
									 | 89 | 91 | 97 | 97 | 
| 
										Price vs. Earnings (P/E)
									 | 53 | 59 | 87 | 97 | 
| 
										Price vs. Book (P/B)
									 | 14 | 45 | 71 | 92 | 
| 
										Dividend Yield
									 | 1 | 1 | 1 | 1 | 
| 
										
										Value
									 | 32 | 60 | 77 | 78 | 
| Metrics | Current | 2024 | 2023 | 2022 | 
|---|---|---|---|---|
| 
										Revenue Growth
									 | 9 | 21 | 8 | 16 | 
| 
										Profit Growth
									 | 55 | 32 | 37 | 32 | 
| 
										Capital Growth
									 | 16 | 51 | 49 | 51 | 
| 
										Stock Returns
									 | 63 | 80 | 72 | 24 | 
| 
										
										Growth
									 | 15 | 40 | 31 | 15 | 
| Metrics | Current | 2024 | 2023 | 2022 | 
|---|---|---|---|---|
| 
										Leverage
									 | 2 | 3 | 4 | 5 | 
| 
										Refinancing
									 | 9 | 13 | 13 | 22 | 
| 
										Liquidity
									 | 37 | 51 | 32 | 23 | 
|  | 6 | 12 | 6 | 4 | 
Discover high‑ranked alternatives to Teva Pharmaceutical Industries and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.
30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.